All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM
Featured:
Timothy M. SchmidtVideo series
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Mutiple Myeloma Hub spoke to Timothy M. Schmidt, University of Wisconsin-Madison, Madison, US. We asked about updates to the NCCN guidelines for the diagnosis and treatment of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM).
For MGUS, Schmidt discusses the addition of the new term, 'monoclonal gammopathy of neurological significance', for patients with IgM polyneuropathy. For SMM, Schmidt highlights the use of the 20:2:20 risk stratification criteria to identify high-risk SMM and discusses treatment options for this group of patients.
More from this series:
The latest on SMM
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?